Company Overview
Snapshot
Founded in May 2014 by Haim Neerman, Noam Shomron, and Tomer Jackman, Variantyx operates with 201–500 employees. The company has raised $131.5 million across 10 funding rounds from 12 investors.
Business overview
Variantyx is a molecular diagnostics laboratory specializing in innovative solutions for genetic disorders, reproductive health, and precision oncology. The company leverages its proprietary whole genome analysis platform to provide comprehensive diagnostic capabilities, aiming to enhance personalized treatment recommendations, accelerate diagnosis timelines, and reduce healthcare costs. Variantyx offers a range of test options, from targeted panels to comprehensive analyses, all performed on its whole genome platform, serving the digital healthcare, pharmaceuticals, and laboratory sectors.
Strategic signal
In September 2024, Variantyx launched Genomic Unity® 2.0, introducing the first combined short- and long-read whole genome sequencing test to the market. This innovation signals a significant advancement in genomic diagnostics, offering enhanced capabilities for identifying complex genetic variations and providing a more complete picture for patient diagnoses. For investors, this demonstrates Variantyx's continued leadership in genomic technology and its potential to capture a larger share of the precision medicine market by addressing previously unmet diagnostic needs.
Log in to access full profile ›Company Intelligence Q&A
- What was a key product launch for Variantyx in late 2024?
- In September 2024, Variantyx launched Genomic Unity® 2.0, which is the first combined short- and long-read whole genome sequencing test available in the market.
- What new offering did Variantyx launch in November 2023?
- In November 2023, Variantyx expanded its reproductive health offerings by launching a direct replacement for Chromosomal Microarray Analysis.
- What was a significant funding event for Variantyx in October 2022?
- In October 2022, Variantyx secured an additional $20 million in debt financing from Kreos Capital.